Can Eliquis Be Used for a "Leaky Valve"?
Yes, Eliquis (apixaban) can be used in patients with a leaky (regurgitant) native heart valve, provided they have atrial fibrillation and do not have moderate-to-severe mitral stenosis or a mechanical prosthetic valve. 1
Key Distinction: What Type of Valve Disease Matters
The critical issue is not whether you have a leaky valve, but rather which specific valve condition you have:
Eliquis IS Appropriate For:
- Mild-to-moderate native valve regurgitation (leaky valves) including:
- Bioprosthetic valves (>3 months post-op) 1
- Valve repair (>3 months post-op) 1
Eliquis IS CONTRAINDICATED For:
- Mechanical prosthetic heart valves 2, 3, 4
- Moderate-to-severe mitral stenosis (usually rheumatic) 2, 1
The Evidence Supporting Use in Leaky Valves
The 2018 EHRA guidelines introduced a practical classification system (EHRA Type 1 vs Type 2) that clarifies this 1:
- EHRA Type 1 = Must use warfarin (mechanical valves, moderate-severe mitral stenosis)
- EHRA Type 2 = Can use DOACs like Eliquis (all other native valve disease, including regurgitation)
Clinical trial data strongly supports this approach: In the ARISTOTLE trial, over 26% of patients (4,808 out of 18,201) had moderate or severe valvular heart disease 5. Specifically:
- 3,382 patients had moderate-severe mitral regurgitation
- 842 had aortic regurgitation
- 324 had aortic stenosis
Apixaban showed consistent superiority over warfarin across all valve disease subtypes for stroke prevention and bleeding reduction, with no evidence of differential treatment effect 6, 5.
Important Clinical Considerations
For Mitral Regurgitation:
Apixaban demonstrated similar efficacy and safety compared to warfarin (HR 0.69 for stroke/systemic embolism vs warfarin) 6. Event rates were comparable to patients without valve disease.
For Aortic Stenosis:
While apixaban remains effective, be aware that patients with aortic stenosis have inherently higher baseline risk of stroke (3.47 vs 1.36 per 100 patient-years), bleeding, and death compared to those without AS 6. This reflects the severity of their underlying disease, not a problem with apixaban itself.
After Valve Repair:
Real-world data from 127 patients after mitral valve repair showed apixaban had similar rates of bleeding and thromboembolism compared to warfarin 7. Most patients (99%) were also on aspirin.
Dosing and Monitoring
- Use standard dosing (5 mg twice daily) unless specific dose-reduction criteria are met 2
- No routine monitoring required (unlike warfarin) 1
- The FDA label explicitly states Eliquis is not recommended in prosthetic heart valves 3, but this refers specifically to mechanical valves based on the failed ARISTOTLE-MI trial 4
Common Pitfalls to Avoid
Don't confuse "valvular AF" terminology: The outdated term "non-valvular AF" excluded mechanical valves and moderate-severe mitral stenosis—it did NOT exclude regurgitant valve disease 1
Don't assume all valve disease requires warfarin: Only mechanical valves and moderate-severe mitral stenosis are absolute contraindications 2, 1
Don't use apixaban in rheumatic mitral stenosis: Even if "mild," rheumatic etiology suggests warfarin may be preferred 1
Verify the indication: Eliquis is approved for stroke prevention in atrial fibrillation—not for anticoagulation of the valve disease itself 3. The patient must have AF or another approved indication.